Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Date:8/19/2007

in India, Cotara is currently in a dosimetry and dose confirmation trial in glioblastoma patients at leading U.S. academic brain cancer centers. Cotara has been granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection in the U.S. and India with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the Company will not be able to enroll a sufficient number of patients to complete the clinical study, the risk that enrollment will be slower than expected, the risk that the results from the clinical study will not be consistent with the results from the previous clinical studies supporting the potential efficacy of Cotara in brain cancer, and the un
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... -- QT Vascular Ltd., together with its subsidiaries ("QT Vascular" ... design, assembly and distribution of advanced therapeutic solutions for ... into an agreement with a group of investors (the ... This funding will strengthen the Group,s working capital which ... Dr. Eitan Konstantino , Ph.D., ...
(Date:7/27/2015)... York , July 27, 2015 ... Research "Bionics Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 7.96 billion in 2014, growing at a ... USD 20.49 billion in 2021. The global bionics ... number of accidents, which is leading to paralysis or amputation ...
(Date:7/27/2015)... , July 27, 2015 Dynatronics Corporation (NASDAQ: DYNT ... Solaris therapeutic modality products. This approval allows the company to sell ... countries around the world. "Receiving the CE Mark represents ... stated Kelvyn H. Cullimore Jr. , president and CEO of ... network into China , Japan ...
Breaking Medicine Technology:QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4Dynatronics Awarded CE Mark Approval for Its Solaris Products 2
... trauma or,noise-induced hearing loss. By any name, it,s the ... 28 million Americans,have impaired hearing; for as many as ... December 2007 issue of Harvard Men,s,Health Watch., Acoustic ... exposure,is the most common cause, but recreational noise -- ...
... Proven to Significantly Improve Overall Survival in ... Patients ... 19 ,Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq:,ONXX) today ... a supplemental New Drug Application for Nexavar(R) (sorafenib),tablets for the ...
Cached Medicine Technology:Your Hearing May be at Risk, Says Harvard Men's Health Watch 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 3Nexavar First FDA-Approved Drug Therapy for Liver Cancer 4Nexavar First FDA-Approved Drug Therapy for Liver Cancer 5Nexavar First FDA-Approved Drug Therapy for Liver Cancer 6
(Date:7/27/2015)... ... ... Throughout its 20 year history, Doctors on Liens has pioneered ... basis. As the personal injury and medical industries have changed, Doctors on Liens ... pain management physicians, to psychologists and more. And while many of these offices ...
(Date:7/27/2015)... ... July 27, 2015 , ... Recently, 10 Best Water ... respected water brands also made the organization’s list. As its name clearly indicates, 10 ... available. Here is a description of the top three brands, along with a listing ...
(Date:7/27/2015)... Dallas, Texas (PRWEB) , ... July 27, 2015 ... ... the use of fullerenes in medical and diagnostics applications is rapidly increasing and ... drug delivery and cancer treatment, they are increasingly being evaluated for use in ...
(Date:7/27/2015)... ... , ... Boston IVF, the first Massachusetts egg freezing center to assist in ... Nantucket Island for women who wish to learn more about their fertility and egg ... Chins Way, Nantucket Island 02554 from 4:30-6:30pm. , This casual and informative event will ...
(Date:7/27/2015)... ... 27, 2015 , ... Standifer Insurance Group, a locally owned insurance company with ... Conquest, a specialized camp for young people who have been hospitalized in the burn ... and four night curriculum designed to give burn survivors between the ages of 6-17 ...
Breaking Medicine News(10 mins):Health News:Doctors on Liens Adds Highly Respected Physical Therapy Office in Los Angeles 2Health News:Best Water Brand Awards Presented by 10 Best Water 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 3Health News:Boston IVF to Host Egg Freezing Event in Nantucket on August 6th at 4:30pm 2Health News:Boston IVF to Host Egg Freezing Event in Nantucket on August 6th at 4:30pm 3Health News:Standifer Insurance Group and Camp Conquest Plan Joint Charity Initiative to Assist Hospitalized Children Suffering from Burn Injuries 2Health News:Standifer Insurance Group and Camp Conquest Plan Joint Charity Initiative to Assist Hospitalized Children Suffering from Burn Injuries 3
... -- A common form of heart trouble called diastolic ... an increased risk of heart failure, new research shows. ... age, the heart,s left ventricle fills with blood in an ... The new study included more than 2,000 people aged ...
... HealthDay Reporter , TUESDAY, Aug. 23 (HealthDay News) -- ... regular medications for chronic conditions during their stay and ... say. Patients treated in the intensive care unit ... medication schedule after discharge, probably because there are so ...
... chemicals can be like putting together a puzzle. University ... the pieces together to more efficiently build complex molecules, ... by chemistry professor Martin Burke, the team published its ... Angewandte Chemie . Burke,s group is known for ...
... researchers have proposed in a new study a different ... using data from other similar chemicals. For ... have enough information to understand all of the effects ... this, the European Union enacted the REACH regulation, which ...
... patients treated at a U.S. military hospital in Afghanistan ... in the September issue of Infection Control and ... Healthcare Epidemiology of America. The findings underscore the need ... both soldiers and local patients are treated, the study,s ...
... -- The amount of fighting and arguing in your marriage ... study suggests. Ohio State University researchers looked at data ... 2000. Based on how often participants said they disagreed with ... high-conflict marriages. There was little change in any of ...
Cached Medicine News:Health News:Common Heart Dysfunction Can Help Bring on Heart Failure 2Health News:Mainstay Meds Often Cut Off Accidentally After Hospital Stay 2Health News:Mainstay Meds Often Cut Off Accidentally After Hospital Stay 3Health News:A new set of building blocks for simple synthesis of complex molecules 2Health News:Scientists develop new approaches to predict the environmental safety of chemicals 2Health News:Study: Afghan patients a common source of drug-resistant bacteria 2Health News:Couples Who Don't Fight Much Aren't Likely to Start 2
... Richmond Products includes the four demonstration plates, the ... for a total of 24 plates. Each of ... and clean page selection. The test also includes ... laminated copy of the score sheet. The score ...
... charts are recognized internationally as a ... deficiency. With normal color perception, the ... visible. Each color test plate in ... printed to measure incrementally higher color ...
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Medicine Products: